Zafgen has something to cheer as diabetes drug makes the cut in PhII study, quelling cardio safety fears

After being plagued by a laundry list of setbacks that culminated in the desertion of its obesity drug and the departure of its CEO, Zafgen finally has some good news to report. Data from a cohort of a mid-stage study suggested that its now-lead diabetes drug induced statistically significant improvements in blood sugar levels and weight loss.